# Neuralink — Healthcare Investment Intelligence

> other · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) founded by Elon Musk in 2016. The company received FDA approval in May 2023 and is conducting clinical trials such as the PRIME Study for patients with spinal cord injuries or ALS.[1][2]

## Key facts (as of 2026-06-12)
- Sector: other
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Consensus recommendation: hold
- Conviction: 5
- Intelligence score: 15/100
- Analyses: 1
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-18. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.